Oncothyreon to receive milestone payment from Merck KGaA
Oncothyreon Inc. announced that it has completed the transfer of certain assays and manufacturing technology related to Stimuvax(R) (BLP25 liposome vaccine) to Merck KGaA of Darmstadt, Germany, triggering a payment to Oncothyreon of $3 million. The payment will be made under the terms of the amended and restated supply agreement signed in August 2007.
Stimuvax is an investigational therapeutic cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a glycoprotein antigen widely expressed on common cancers. Merck KGaA currently is conducting a global Phase 3 trial of Stimuvax known as START (Stimulating Targeted Antigenic Responses To NSCLC). START is a randomized, double-blind, placebo-controlled study that will evaluate patients with documented unresectable stage III NSCLC who have had a response or stable disease after at least two cycles of platinum based chemo-radiotherapy. The trial is expected to enroll more than 1,300 patients in approximately 30 countries.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Herbert_Dudley_Purves

This is how the superbug Pseudomonas aeruginosa reacts to antibiotics - Specific properties might become targets for drugs
Category:Swiss_biochemists
Validation of the dossier for drug approval of Biofrontera's BF-200 ALA successful
All tied up: Tethered protein provides long-sought answer
Naturalpha launches a clinical investigation center for nutrition
Biosignal: Collaboration with international company on agriculture applications - Evaluation for use in crop protection to be conducted over 9 months
Modified_starch
Indivumed to study the integrity of biospecimen sampling procedures for the U.S. National Cancer Institute - Analysis of biopsy sampling procedures a prerequisite for the development of future individualized cancer therapies
